SlideShare a Scribd company logo
1 of 25
Download to read offline
Immunogenicity of Biologicals:
Clinical Consequences
Dr. S.К. Zyryanov
Professor, Chair of Clinical Pharmacology,
N.I. Pirogov Russian National Research Medical
University (RNRMU)
Main Definitions
Biological
A drug, the active substance of which is a
biological substance derived or extracted from
a biological source, including using one or
more of the above mentioned biotechnological
methods: rDNA technology; controlled
expression of genes encoding bioactive protein
production; hybrid and monoclonal antibody
methods
What is the difference between biologicals and
low-molecular drugs?
• Molecular weights
• Structure complexity
• Features:
– Structural and physical & chemical properties
– Protein purification degree
– Biological activity
• Stability
• Immunogenicity!
Crommelin DJA, et al. Int J Pharm 2003;266:3-16.
Factors Influencing Immunogenicity
Schellekens H. Nat Rev Drug Discov 2002:457–62
Sequence variation Glycosylation
Human Bacterial
Contaminants and
impurities (from
initial production
or downstream
processing)
Formulation
Route of
administration Dose
February
Treatment duration Assay technologies Patient characteristics Unknown factors
Immunogenicity
Frequency of Immune Response to Tumor
Necrosis Factor (TNF) Inhibitors
Humira/Adalumimab % of patients with antibodies
Juvenile idiopathic arthritis 5.9% (+MTX) 25.6% (-MTX)
Rheumatoid arthritis 0.6% (+MTS) 12.4% (-MTX)
Remicaid / Infliximab
Adults 38% (3 mg/kg) 12% (6 mg/kg)
Children 2.9%
Enbrel/ Etanerzept
Rheumatoid arthritis 6%
Psoriatic arthritis 7.5%
Ankylozing spondyloatritis 2%
Adult psoriasis 7%
Child psoriasis 9.7%
Juvenile idiopathic artritis 3%
MTX – metatrexat
Reported Frequencies of β-1a Interferon
Antibody Formation
Extract from the article by Bertolotto et al J Neurology 2004
Study Determination of positive response to
neutralizing antibodies (Нат)
Analysis
method
Dosage (IM,
weekly)
Share of Нат-positive patients
(%)
Jacobs et al. (1996) [14] Not reported N/A 30 mcg 22*
Herden et al. (1999) [10] Min. 1 out of 20 titres CEA 30 mcg 5
Rudick et al. (1998) [34] Min. 1 out of 20 titres CEA 30 mcg 6
Jacobs et al. (2000) [13] Min. 1 out of 20 titres CEA 30 mcg 2
Clanet et al. (2002) [4] Min. 1 out of 20 titres CEA 30 mcg
60 mcg
2,3
5,8
IM – intramuscular; CEA – cytopathic effect analysis
* Нат frequency was higher than in earlier studies because Jacobs et al. [14] had conducted studies using a non-commercial drug before
the production process was improved.
r-protein Indications Immunogenicity
Insulin Diabetes Approx. 44% of patients (5%
IgE)
Growth hormone GH-deficiency 3%-16% of patients
Erythropoietin Anaemia 1:10 000 patients
VIII factor Haemophilia Approx. 35% of patients
IFN- Hepatitis etc. Approx. 25% of patients
IL-2 Certain tumors 20%-100% of patients
Immunogenicity of Recombinant Therapeutic
Proteins
(H.Schellekens, 2002)
Antibody Formation Consequences
• Efficacy loss
– Interferon alpha 2
– Interferon beta
– TNF inhibitors
– Beta agalsydase
– And many others
• Cross-neutralization of endogenous factors
– Erythropoietin (EPO)
– Growth and megakaryocyte development factor (GMDF)
• Anaphylaxis reaction; serum reaction
– Monoclonal antibodies
Antibody analysis method Interferon drug
Efficacy reduction (relapses, NMR or
bio markers)
PRISMS 4 (2005) CEA Rebif® Yes
IFNβ research group (1996) CEA Betaferon® Yes
IFNβ European Research
Group (1998) and (1999)
CEA Betaferon®
Deisenhammer et al. (1999)
MxA protein interferon alpha
test
Betaferon® Yes
Cook et al. (2001) CEA; neopterin test Avonex®; Betaferon® Yes
Vallittu et al. (2002) CEA; MxA protein test Rebif® 22 Yes
Bertolotto et al. (2005) CEA; MxA protein i-RNA test Avonex®; Rebif® 22; Betaferon® Yes
Pachner et al. (2003)
CEA; MxA protein i-RNA test;
ОАС
Not reported Biomarker reduction
Malucchi et al. (2004) CEA Avonex®; Rebif® 22; Betaferon® Yes
Petkau et al. (2004) CEA; MxA protein test Betaferon® Yes
Perini et al. (2004) CEA Avonex®; Rebif® 22; Betaferon® Yes
Kappos et al. (2005) CEA
Avonex® 30 mcg;
Avonex® 60 mcg
Yes
Sorensen et al. (2003) CEA
Avonex® 30 mcg OW; Rebif® 22
mcg OW; Rebif® 22 mcg TTW;
Betaferon® 8 ММЕ/2days
Interferon neutralization
.Extract from the article by R.A. Farrell and G. Giovannoni, Measuring and management of anti-interferon beta antibodies in subjects with multiple
sclerosis, Mult. Scler. 13 (5) (Jun 2007), pp. 567–577.
ß-interferon neutralizing antibodies reduce the multiple sclerosis treatment efficacy
Fig. 5. States of stable disease activity and remissionin patients with and without adalimumab
(ААА) antibodies
Bartelds, G. M. et al. JAMA 2011;305:1460-1468
Copyright restrictions may apply.
Weeks Weeks Weeks
Stable remissionStable minimum activity
Stable minimum activity
Patientshare
Patientshare
Patientshare
Number of persons at risk Number of persons at risk Number of persons at risk
UI/ml
UI/ml
Impact of Antibodies on Beta-
Agalsidase Efficacy in Fabry Disease
Benichou et al. Molecular tools and genetics (2008)
Shareofpatients
withnon-zeroscore
Serum negative Low titers Medium titers High titers
Biosimilar = generic
‘Biosimilar’ is a biological that is similar to the originator
biological but is not its generic due to differences in the initial
raw materials and manufacturing of the originator biological
and of the biosimilar…
Source: translated from Article 10 (2) b of Directive 2001/83 as amended
Why should we be cautious speaking about
substitutability of biologicals?
Regulation of biosimilar manufacturing and application in EC
Amended Directive 2001/83/EC
(2003/63/EC, 2004/27/EC)
Overarching Guidelines
(CHMP/437/04)
Quality Guidelines
(CHMP/49348/05)
Non-Clin & Clin Guidelines
(CHMP/42832/05)
r-Human Insulin Guidance
(CHMP/42832/05)
Somatropin Guidance
(CHMP/94528/05)
r-GCSF Guidance
(CHMP/31329/05)
r-Erythropoeitin Guidance
(CHMP/94526/05)
Immunogenicity Guidance
(CHMP/14327/06)
Low Molecular Weight Heparin
Guidance (CHMP/118264/2007)
r--Interferon Guidance
(CHMP/102046/06)
Guidelines under preparation
Findings of the Сomparative Alpha Epoietin
Drug Study
Singh A. K.
Brigham and Women’s hospital & Harvard Medical School,
Boston, USA.
World Congress of Nephrology – Apr 22, 2007
47 samples from the following countries were tested: Argentine,
Brazil, Columbia, India, Indonesia, Iran, Jordan, Korea, Lebanon,
Nigeria, Philippines, Russia, Thailand, Venezuela, Viet Nam and
Yemen
The samples were tested according to the European
Pharmacopoeia quality requirements to alpha epoietin. Eprex®
(alpha epoietin) was used as a reference product.
Singh AK. Poster presented at the World Congress of Nephrology, 21-25 April 2007, Rio de Janeiro, Brazil
15
Singh A. K. Study Findings
 pH
 9 samples deviated from the specification requirements
 Osmosis
 21 samples had greater osmosis
 Protein and erythropoietin content
 1 sample did not meet the specification requirements as concerns the
protein content
 8 samples had excess erythropoietin
 In vitro biological sample
1 sample did not meet the specification requirements
 18 samples deviated from the specification requirements
 In vivo efficacy
48%-163% efficacy differences
 9 samples did not meet the specification requirements
 6 samples deviated from the specification requirements
 Bacterial endotoxin
2 samples contained bacterial endotoxin
Singh AK. Poster presented at the World Congress of Nephrology, 21-25 April 2007, Rio de Janeiro, Brazil
16
 Aggregate content
 29 samples exceeded the specification by the number of aggregates
 7 samples had more than 1% and less than 2% aggregates
 4 samples had 2%-4% aggregates
 18 samples had more than 4% aggregates
 Isoform content
 34 samples had excess isoforms, which may reduce the clinical
effect
 9 out of 34 samples had ≥ 3 additional isoforms
Singh A. K. Study Findings
Singh AK. Poster presented at the World Congress of Nephrology, 21-25 April 2007, Rio de Janeiro, Brazil
Alpha Epoietin Drug Comparative Study
Findings (continued)
Epoietin biosimilar
In-vitro bio
sample
In-vivo efficacy on mice,
%
Bacterial endotoxin
(EU/ml)
Aggregates, %
Standard (Eprex®) 80-125 80-125 < 2.5 < 1
Epocrim1 94 73 < 0.5 < 1
Epocrim2 175 76 < 0.5 2.4
Epokin 1 84 91 < 0.5 1.7
Epokrin 1 167 135 < 0.5 1.2
Epokrin 2 155 117 < 0.5 >4
Epokrin 3 175 149 < 0.5 < 1
Eporon 170 163 < 0.5 > 4
Epoet 141 95 < 0.5 2.7
Gerepo 141 48 < 0.5 > 4
Hemax 1 139 97 < 0.5 > 4
Hemax 2 132 101 < 0.5 > 4
Hemax 3 141 90 < 0.5 > 4
Hypercryte 153 113 < 0.5 > 4
Renogen 110 108 < 0.5 > 4
Vepox 177 57 > 2.5 > 4
Zirop 142 Two failures < 0.5 > 4
Epokim 1
2
3
Epokrin 1
2
3
Eporon
Epovet 1
2
Espogen 1
2
3
Geerepo
Hemax 1
2
3
Hypercryte 1
2
Vepox
Zirop 1
2
Alkali isoforms
Acid isoforms
0 1 2 3 4 5
Total quantity of additional isoforms
Alpha Epoietin Drug Comparative Study Findings
(continued)
Conclusions on Alpha Epoietin drug
Comparative Study Findings:
 Several out of the tested epoietin biosimilars had variable quality and efficacy;
42 out of 47 samples did not meet all European Requirements to alpha
epoietin
 34 samples contained additional alkali isoforms that may reduce clinical drug
efficacy
 2 samples contained bacterial endotoxin that poses risk for the patient’s safety
 22 samples contained more than 2% aggregates that may influence the drug
immunological profile
 Detected differences lead to unpredictable adverse events in clinical practice
 Studied biosimilars had differences in various series of one and the same drug
Specialists applying epoietin generics in their practice should track their
efficacy and safety attentively
Singh AK. Poster presented at the World Congress of Nephrology, 21-25 April 2007, Rio de Janeiro, Brazil
20
July 09ASH
Abstract &
Poster #
Immunogenicity of Low Molecular Weight Heparins and Their
Biosimilars
W.P.Jeske
J.Walenga
HIT Antibodies Synthesis Induction
In Vitro Cross-Reactivity of Branded LMWHs (1 g/mL) with
HIT Antibodies in the Platelet Aggregation Assay
1 2 3 4 5 6 7 8
%Aggregation
0
2 5
5 0
7 5
1. Saline 5. Reviparin
2. Dalteparin 6. Parnaparin
3. Enoxaparin 7. Tinzaparin
4. Nadroparin 8. Heparin
In Vitro Cross-Reactivity of Branded LMWHs (1 g/mL) with
HIT Antibodies in the Platelet Aggregation Assay
1 2 3 4 5 6 7 8
%Aggregation
0
2 5
5 0
7 5
1. Saline 5. Reviparin
2. Dalteparin 6. Parnaparin
3. Enoxaparin 7. Tinzaparin
4. Nadroparin 8. Heparin
In Vitro Cross-Reactivity of Biosimilar Versions of Enoxaparin and
Dalteparin (1 g/mL) with HIT Antibodies in the
Platelet Aggregation Assay
1 2 3 4 5 6 7
%Aggregation
0
2 5
5 0
7 5
1. Saline 5. Dilutol
2. Clenox 6. Lupenox
3. Cutenox 7. Daltehep
4. Dripanina
In Vitro Cross-Reactivity of Biosimilar Versions of Enoxaparin and
Dalteparin (1 g/mL) with HIT Antibodies in the
Platelet Aggregation Assay
1 2 3 4 5 6 7
%Aggregation
0
2 5
5 0
7 5
1. Saline 5. Dilutol
2. Clenox 6. Lupenox
3. Cutenox 7. Daltehep
4. Dripanina
Clinical case: Clexan
substitution with a generic
A patient had taken Clexan for 4 years
without complications. Upon transition
to the enoxaparin biosimilar, the
patient experienced 2 life-
threatening haemorrhages within 4
months from the onset of use.
This case suggests that FDA should follow
EMA recommendation to have a more
stringent biosimilar approval procedure:
bioequivalency and the studies that display
safety and efficacy similar to those of the
originator before approval of the
biosimilar.
Biologicals and Biosimilars
Clinical Case
М.V. Belov, A.S. Petrochenko, E.M. Pozdnyakova, V.V. Yakusevich. Efficacy of different tromboembolic complication prevention methods in clinical practice
(retrospective study). Clinical Pharmacology and Treatment, 2012, 21 (4)
Biologicals and Biosimilars
Clinical Pre-Surgical Practice Findings
Goal. Assessing the efficacy of tromboembolic
consequences prevention in the pre-surgery
period using unfractionated heparin and
enoxaparin biosimilar.
Findings. Frequency of LLVT did not reliably differ
in the patients receiving unfractionated heparin
and enoxaparin biosimilar.
Opinion. Lack of pronounced advantages of
enoxaparin biosimilar to unfractionated heparin
may be due to heterogeneity of the raw materials
used for manufacturing of the originator and
enoxaparin and biosimilar.
Enoxaparin biosimilar did not differ from
unfractionated heparin in terms of LLVT prevention
efficacy.
Frequency (%) of lower limb venous thrombosis
before surgery (LLVT)
Enoxaparin biosimilarUnfractionated
heparin
Immunogenicity Forecasting
 Establishment of physical and chemical
properties
 Epitope analysis (in silico/in vitro)
 Reactions with the patient’s serum
 Animal tests
• Conventionally used animals (relative
immunogenicity?)
• Subprimates
• Immune tolerant transgenic mice
Biosimilar Immunogenicity Issues
 The existing analysis methods do not fully predict
biological properties
 The immune system is able to notice changes in a
drug, which are not detected using analytical methods
 Immunogenicity of biologicals may have significant
clinical consequences
24
Immunogenicity and Biosimilar
Aspects
 Immunogenicity can only be detected in clinical
studies
 Problems of trackability and substitutability with
similars
 Substitution must not be there the immunogenicity
risk factor is
 Immunogenicity may make a patient immune to a
whole drug class
 Standardization

More Related Content

What's hot

Protein micro array
Protein micro arrayProtein micro array
Protein micro arraykrupa sagar
 
Applications of Genomic and Proteomic Tools
Applications of Genomic and Proteomic ToolsApplications of Genomic and Proteomic Tools
Applications of Genomic and Proteomic ToolsRaju Paudel
 
Biopharmaceuticals and biosimilar drugs
Biopharmaceuticals and biosimilar drugsBiopharmaceuticals and biosimilar drugs
Biopharmaceuticals and biosimilar drugsDr. Mohit Kulmi
 
Application of protein engineering
Application of protein engineering Application of protein engineering
Application of protein engineering Akshay Parmar
 
Nucleic acid theraprutics
Nucleic acid therapruticsNucleic acid theraprutics
Nucleic acid therapruticsDr Qureshi
 
Recombinant therapeutic proteins
Recombinant therapeutic proteinsRecombinant therapeutic proteins
Recombinant therapeutic proteinsBeenish Choudhary
 
Lecture 8 drug targets and target identification
Lecture 8 drug targets and target identificationLecture 8 drug targets and target identification
Lecture 8 drug targets and target identificationRAJAN ROLTA
 
Study of cloning vectors, restriction endonucleases and DNA ligase.
Study of cloning vectors, restriction endonucleases and DNA ligase.Study of cloning vectors, restriction endonucleases and DNA ligase.
Study of cloning vectors, restriction endonucleases and DNA ligase.Tushar Morankar
 
Molecular Pharmacology-Receptor Desensitization
Molecular Pharmacology-Receptor DesensitizationMolecular Pharmacology-Receptor Desensitization
Molecular Pharmacology-Receptor Desensitizationvaruntvs1811
 
Stability Of Peptides And Proteins
Stability Of Peptides And ProteinsStability Of Peptides And Proteins
Stability Of Peptides And ProteinsThilak Chandra
 
Enzyme Immobilization and Applications
Enzyme Immobilization and ApplicationsEnzyme Immobilization and Applications
Enzyme Immobilization and ApplicationsMadhukar Vedantham
 
Cytochorme p450 enzyme
Cytochorme p450 enzymeCytochorme p450 enzyme
Cytochorme p450 enzymeROHIT
 
Protein engineering saurav
Protein engineering sauravProtein engineering saurav
Protein engineering sauravSaurav Das
 
ANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDESANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDESayanarkumar19
 

What's hot (20)

ZONE ELECTROPHORESIS
ZONE ELECTROPHORESISZONE ELECTROPHORESIS
ZONE ELECTROPHORESIS
 
Protein micro array
Protein micro arrayProtein micro array
Protein micro array
 
Antisense therapy
Antisense therapy Antisense therapy
Antisense therapy
 
Applications of Genomic and Proteomic Tools
Applications of Genomic and Proteomic ToolsApplications of Genomic and Proteomic Tools
Applications of Genomic and Proteomic Tools
 
Biopharmaceuticals and biosimilar drugs
Biopharmaceuticals and biosimilar drugsBiopharmaceuticals and biosimilar drugs
Biopharmaceuticals and biosimilar drugs
 
Application of protein engineering
Application of protein engineering Application of protein engineering
Application of protein engineering
 
Nucleic acid theraprutics
Nucleic acid therapruticsNucleic acid theraprutics
Nucleic acid theraprutics
 
Recombinant therapeutic proteins
Recombinant therapeutic proteinsRecombinant therapeutic proteins
Recombinant therapeutic proteins
 
Lecture 8 drug targets and target identification
Lecture 8 drug targets and target identificationLecture 8 drug targets and target identification
Lecture 8 drug targets and target identification
 
Hybridoma technology
Hybridoma technologyHybridoma technology
Hybridoma technology
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
Gene delivery system
Gene delivery systemGene delivery system
Gene delivery system
 
Study of cloning vectors, restriction endonucleases and DNA ligase.
Study of cloning vectors, restriction endonucleases and DNA ligase.Study of cloning vectors, restriction endonucleases and DNA ligase.
Study of cloning vectors, restriction endonucleases and DNA ligase.
 
Molecular Pharmacology-Receptor Desensitization
Molecular Pharmacology-Receptor DesensitizationMolecular Pharmacology-Receptor Desensitization
Molecular Pharmacology-Receptor Desensitization
 
Peptides
PeptidesPeptides
Peptides
 
Stability Of Peptides And Proteins
Stability Of Peptides And ProteinsStability Of Peptides And Proteins
Stability Of Peptides And Proteins
 
Enzyme Immobilization and Applications
Enzyme Immobilization and ApplicationsEnzyme Immobilization and Applications
Enzyme Immobilization and Applications
 
Cytochorme p450 enzyme
Cytochorme p450 enzymeCytochorme p450 enzyme
Cytochorme p450 enzyme
 
Protein engineering saurav
Protein engineering sauravProtein engineering saurav
Protein engineering saurav
 
ANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDESANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDES
 

Viewers also liked

Viewers also liked (19)

Immunogenicity 2016
Immunogenicity 2016Immunogenicity 2016
Immunogenicity 2016
 
10 Barry Cherney IABS
10 Barry Cherney  IABS10 Barry Cherney  IABS
10 Barry Cherney IABS
 
Antigen structure and immunogenicity
Antigen structure and immunogenicityAntigen structure and immunogenicity
Antigen structure and immunogenicity
 
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological ProductsFDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
 
Antigen antibody
Antigen antibodyAntigen antibody
Antigen antibody
 
Innate and adaptive immunity
Innate and adaptive immunityInnate and adaptive immunity
Innate and adaptive immunity
 
DNA Extraction and Isolation
DNA Extraction and IsolationDNA Extraction and Isolation
DNA Extraction and Isolation
 
2 antigens, immunogens, epitopes, and haptens
2 antigens, immunogens, epitopes, and haptens2 antigens, immunogens, epitopes, and haptens
2 antigens, immunogens, epitopes, and haptens
 
Adaptive immunity
Adaptive immunityAdaptive immunity
Adaptive immunity
 
Plasmids
PlasmidsPlasmids
Plasmids
 
Monoclonal antibody
Monoclonal antibodyMonoclonal antibody
Monoclonal antibody
 
monoclonal antibodies
monoclonal antibodiesmonoclonal antibodies
monoclonal antibodies
 
Autoimmunity
AutoimmunityAutoimmunity
Autoimmunity
 
Genetic engineering
Genetic engineeringGenetic engineering
Genetic engineering
 
MONOCLONAL ANTIBODIES
MONOCLONAL ANTIBODIESMONOCLONAL ANTIBODIES
MONOCLONAL ANTIBODIES
 
Bacterial plasmids
Bacterial plasmidsBacterial plasmids
Bacterial plasmids
 
Lecture 4, fall 2014 pdf
Lecture 4, fall 2014 pdfLecture 4, fall 2014 pdf
Lecture 4, fall 2014 pdf
 
Dna extraction
Dna extractionDna extraction
Dna extraction
 
Haptens
HaptensHaptens
Haptens
 

Similar to 31. Immunogenicity of Biologicals: Clinical Consequences

West African Sorghum Extract Again Shows Immune Health Benefits : Health-forever
West African Sorghum Extract Again Shows Immune Health Benefits : Health-foreverWest African Sorghum Extract Again Shows Immune Health Benefits : Health-forever
West African Sorghum Extract Again Shows Immune Health Benefits : Health-foreverHealth Forever
 
Traditional Herbal Medicine To Increased Hemoglobin : HEALTH-FOREVER.COM
Traditional Herbal Medicine To Increased Hemoglobin : HEALTH-FOREVER.COMTraditional Herbal Medicine To Increased Hemoglobin : HEALTH-FOREVER.COM
Traditional Herbal Medicine To Increased Hemoglobin : HEALTH-FOREVER.COMHealth Forever
 
Target Validation Academy Of Medical Sciences 1 Dec 2006
Target Validation   Academy Of Medical Sciences 1 Dec 2006Target Validation   Academy Of Medical Sciences 1 Dec 2006
Target Validation Academy Of Medical Sciences 1 Dec 2006Mike Romanos
 
Marketing of Proteins and Peptide Pharmaceuticals
Marketing of Proteins and Peptide PharmaceuticalsMarketing of Proteins and Peptide Pharmaceuticals
Marketing of Proteins and Peptide Pharmaceuticalsguest6c594976
 
Marketing of Protein and Peptide Pharmaceuticals
Marketing of Protein and Peptide PharmaceuticalsMarketing of Protein and Peptide Pharmaceuticals
Marketing of Protein and Peptide Pharmaceuticalssasannasoohi
 
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...Innovation Agency
 
Biomarker Discovery For Early Clin Dev Dublin Oct 2008
Biomarker Discovery For Early Clin Dev   Dublin Oct 2008Biomarker Discovery For Early Clin Dev   Dublin Oct 2008
Biomarker Discovery For Early Clin Dev Dublin Oct 2008Mike Romanos
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized MedicineMichel Dumontier
 
Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...
Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...
Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...Pranav Sopory
 
Genomic proteomics
Genomic proteomicsGenomic proteomics
Genomic proteomicsmeethy
 
Antibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute PanceriatitisAntibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute PanceriatitisSaeed Al-Shomimi
 
drug discovery
drug discoverydrug discovery
drug discoverymarymelna1
 
Drug discovery and development. Introducing
Drug discovery and development. IntroducingDrug discovery and development. Introducing
Drug discovery and development. Introducing7ReeshabhBele
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and developmentrahul_pharma
 

Similar to 31. Immunogenicity of Biologicals: Clinical Consequences (20)

Intravenous immunoglobulin for patients with primary immunodeficiency
Intravenous immunoglobulin for patients with primary immunodeficiencyIntravenous immunoglobulin for patients with primary immunodeficiency
Intravenous immunoglobulin for patients with primary immunodeficiency
 
West African Sorghum Extract Again Shows Immune Health Benefits : Health-forever
West African Sorghum Extract Again Shows Immune Health Benefits : Health-foreverWest African Sorghum Extract Again Shows Immune Health Benefits : Health-forever
West African Sorghum Extract Again Shows Immune Health Benefits : Health-forever
 
Traditional Herbal Medicine To Increased Hemoglobin : HEALTH-FOREVER.COM
Traditional Herbal Medicine To Increased Hemoglobin : HEALTH-FOREVER.COMTraditional Herbal Medicine To Increased Hemoglobin : HEALTH-FOREVER.COM
Traditional Herbal Medicine To Increased Hemoglobin : HEALTH-FOREVER.COM
 
Target Validation Academy Of Medical Sciences 1 Dec 2006
Target Validation   Academy Of Medical Sciences 1 Dec 2006Target Validation   Academy Of Medical Sciences 1 Dec 2006
Target Validation Academy Of Medical Sciences 1 Dec 2006
 
Marketing of Proteins and Peptide Pharmaceuticals
Marketing of Proteins and Peptide PharmaceuticalsMarketing of Proteins and Peptide Pharmaceuticals
Marketing of Proteins and Peptide Pharmaceuticals
 
Marketing of Protein and Peptide Pharmaceuticals
Marketing of Protein and Peptide PharmaceuticalsMarketing of Protein and Peptide Pharmaceuticals
Marketing of Protein and Peptide Pharmaceuticals
 
Homspera march2010
Homspera march2010Homspera march2010
Homspera march2010
 
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
 
1 Dr Gilberto Castañeda Hernández - CINVESTAV
1 Dr Gilberto Castañeda Hernández - CINVESTAV1 Dr Gilberto Castañeda Hernández - CINVESTAV
1 Dr Gilberto Castañeda Hernández - CINVESTAV
 
Biomarker Discovery For Early Clin Dev Dublin Oct 2008
Biomarker Discovery For Early Clin Dev   Dublin Oct 2008Biomarker Discovery For Early Clin Dev   Dublin Oct 2008
Biomarker Discovery For Early Clin Dev Dublin Oct 2008
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine
 
Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...
Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...
Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...
 
Genomic proteomics
Genomic proteomicsGenomic proteomics
Genomic proteomics
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
Antibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute PanceriatitisAntibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute Panceriatitis
 
drug discovery
drug discoverydrug discovery
drug discovery
 
interchangeability
interchangeabilityinterchangeability
interchangeability
 
18. Dr. Andrey Vasiliev - Ministry of Health (Russian Federation)
18. Dr. Andrey Vasiliev - Ministry of Health (Russian Federation)18. Dr. Andrey Vasiliev - Ministry of Health (Russian Federation)
18. Dr. Andrey Vasiliev - Ministry of Health (Russian Federation)
 
Drug discovery and development. Introducing
Drug discovery and development. IntroducingDrug discovery and development. Introducing
Drug discovery and development. Introducing
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 

More from International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

More from International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (20)

Peter Hotez, Baylor College of Medicine
Peter Hotez,  Baylor College of MedicinePeter Hotez,  Baylor College of Medicine
Peter Hotez, Baylor College of Medicine
 
Session1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European UnionSession1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European Union
 
Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA /
Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA / Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA /
Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA /
 
Session 4 Sabine Walser Council of Europe / Legal framework necessary for eff...
Session 4 Sabine Walser Council of Europe / Legal framework necessary for eff...Session 4 Sabine Walser Council of Europe / Legal framework necessary for eff...
Session 4 Sabine Walser Council of Europe / Legal framework necessary for eff...
 
Session 4: Domenico Di Giorgio AIFA Italy / SPOC model cooperation against co...
Session 4: Domenico Di Giorgio AIFA Italy / SPOC model cooperation against co...Session 4: Domenico Di Giorgio AIFA Italy / SPOC model cooperation against co...
Session 4: Domenico Di Giorgio AIFA Italy / SPOC model cooperation against co...
 
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
 
Session 4: Sheuan Lee, International Council of Nurses (ICN) / Practices and ...
Session 4: Sheuan Lee, International Council of Nurses (ICN) / Practices and ...Session 4: Sheuan Lee, International Council of Nurses (ICN) / Practices and ...
Session 4: Sheuan Lee, International Council of Nurses (ICN) / Practices and ...
 
Session 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...
Session 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...Session 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...
Session 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...
 
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
 
Afternoon Session Opening: Jim Dahl, Partnership for Safe Medicines
Afternoon Session Opening: Jim Dahl, Partnership for Safe MedicinesAfternoon Session Opening: Jim Dahl, Partnership for Safe Medicines
Afternoon Session Opening: Jim Dahl, Partnership for Safe Medicines
 
Session 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...
Session 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...Session 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...
Session 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...
 
Session 2: Scott Kammer, Rx360
Session 2: Scott Kammer, Rx360 Session 2: Scott Kammer, Rx360
Session 2: Scott Kammer, Rx360
 
Opening Session - Cyntia Genole, IFPMA
Opening Session - Cyntia Genole, IFPMAOpening Session - Cyntia Genole, IFPMA
Opening Session - Cyntia Genole, IFPMA
 
Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...
Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...
Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...
 
Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
Bringing Psoriasis into the Light, Kim kjoeller, Leo PharmaBringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
 
IFPA Psoriasis Presentation
IFPA Psoriasis PresentationIFPA Psoriasis Presentation
IFPA Psoriasis Presentation
 
International Psoriasis Council, Steve O'Dell
International Psoriasis Council, Steve O'DellInternational Psoriasis Council, Steve O'Dell
International Psoriasis Council, Steve O'Dell
 
Manaement of Psoriasis in Low Income Countries
Manaement of Psoriasis in Low Income CountriesManaement of Psoriasis in Low Income Countries
Manaement of Psoriasis in Low Income Countries
 
IFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a Vaccine
IFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a VaccineIFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a Vaccine
IFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a Vaccine
 
The Complex Journey of a Vaccine
The Complex Journey of a VaccineThe Complex Journey of a Vaccine
The Complex Journey of a Vaccine
 

Recently uploaded

Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 

Recently uploaded (20)

Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 

31. Immunogenicity of Biologicals: Clinical Consequences

  • 1. Immunogenicity of Biologicals: Clinical Consequences Dr. S.К. Zyryanov Professor, Chair of Clinical Pharmacology, N.I. Pirogov Russian National Research Medical University (RNRMU)
  • 2. Main Definitions Biological A drug, the active substance of which is a biological substance derived or extracted from a biological source, including using one or more of the above mentioned biotechnological methods: rDNA technology; controlled expression of genes encoding bioactive protein production; hybrid and monoclonal antibody methods
  • 3. What is the difference between biologicals and low-molecular drugs? • Molecular weights • Structure complexity • Features: – Structural and physical & chemical properties – Protein purification degree – Biological activity • Stability • Immunogenicity! Crommelin DJA, et al. Int J Pharm 2003;266:3-16.
  • 4. Factors Influencing Immunogenicity Schellekens H. Nat Rev Drug Discov 2002:457–62 Sequence variation Glycosylation Human Bacterial Contaminants and impurities (from initial production or downstream processing) Formulation Route of administration Dose February Treatment duration Assay technologies Patient characteristics Unknown factors Immunogenicity
  • 5. Frequency of Immune Response to Tumor Necrosis Factor (TNF) Inhibitors Humira/Adalumimab % of patients with antibodies Juvenile idiopathic arthritis 5.9% (+MTX) 25.6% (-MTX) Rheumatoid arthritis 0.6% (+MTS) 12.4% (-MTX) Remicaid / Infliximab Adults 38% (3 mg/kg) 12% (6 mg/kg) Children 2.9% Enbrel/ Etanerzept Rheumatoid arthritis 6% Psoriatic arthritis 7.5% Ankylozing spondyloatritis 2% Adult psoriasis 7% Child psoriasis 9.7% Juvenile idiopathic artritis 3% MTX – metatrexat
  • 6. Reported Frequencies of β-1a Interferon Antibody Formation Extract from the article by Bertolotto et al J Neurology 2004 Study Determination of positive response to neutralizing antibodies (Нат) Analysis method Dosage (IM, weekly) Share of Нат-positive patients (%) Jacobs et al. (1996) [14] Not reported N/A 30 mcg 22* Herden et al. (1999) [10] Min. 1 out of 20 titres CEA 30 mcg 5 Rudick et al. (1998) [34] Min. 1 out of 20 titres CEA 30 mcg 6 Jacobs et al. (2000) [13] Min. 1 out of 20 titres CEA 30 mcg 2 Clanet et al. (2002) [4] Min. 1 out of 20 titres CEA 30 mcg 60 mcg 2,3 5,8 IM – intramuscular; CEA – cytopathic effect analysis * Нат frequency was higher than in earlier studies because Jacobs et al. [14] had conducted studies using a non-commercial drug before the production process was improved.
  • 7. r-protein Indications Immunogenicity Insulin Diabetes Approx. 44% of patients (5% IgE) Growth hormone GH-deficiency 3%-16% of patients Erythropoietin Anaemia 1:10 000 patients VIII factor Haemophilia Approx. 35% of patients IFN- Hepatitis etc. Approx. 25% of patients IL-2 Certain tumors 20%-100% of patients Immunogenicity of Recombinant Therapeutic Proteins (H.Schellekens, 2002)
  • 8. Antibody Formation Consequences • Efficacy loss – Interferon alpha 2 – Interferon beta – TNF inhibitors – Beta agalsydase – And many others • Cross-neutralization of endogenous factors – Erythropoietin (EPO) – Growth and megakaryocyte development factor (GMDF) • Anaphylaxis reaction; serum reaction – Monoclonal antibodies
  • 9. Antibody analysis method Interferon drug Efficacy reduction (relapses, NMR or bio markers) PRISMS 4 (2005) CEA Rebif® Yes IFNβ research group (1996) CEA Betaferon® Yes IFNβ European Research Group (1998) and (1999) CEA Betaferon® Deisenhammer et al. (1999) MxA protein interferon alpha test Betaferon® Yes Cook et al. (2001) CEA; neopterin test Avonex®; Betaferon® Yes Vallittu et al. (2002) CEA; MxA protein test Rebif® 22 Yes Bertolotto et al. (2005) CEA; MxA protein i-RNA test Avonex®; Rebif® 22; Betaferon® Yes Pachner et al. (2003) CEA; MxA protein i-RNA test; ОАС Not reported Biomarker reduction Malucchi et al. (2004) CEA Avonex®; Rebif® 22; Betaferon® Yes Petkau et al. (2004) CEA; MxA protein test Betaferon® Yes Perini et al. (2004) CEA Avonex®; Rebif® 22; Betaferon® Yes Kappos et al. (2005) CEA Avonex® 30 mcg; Avonex® 60 mcg Yes Sorensen et al. (2003) CEA Avonex® 30 mcg OW; Rebif® 22 mcg OW; Rebif® 22 mcg TTW; Betaferon® 8 ММЕ/2days Interferon neutralization .Extract from the article by R.A. Farrell and G. Giovannoni, Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis, Mult. Scler. 13 (5) (Jun 2007), pp. 567–577. ß-interferon neutralizing antibodies reduce the multiple sclerosis treatment efficacy
  • 10. Fig. 5. States of stable disease activity and remissionin patients with and without adalimumab (ААА) antibodies Bartelds, G. M. et al. JAMA 2011;305:1460-1468 Copyright restrictions may apply. Weeks Weeks Weeks Stable remissionStable minimum activity Stable minimum activity Patientshare Patientshare Patientshare Number of persons at risk Number of persons at risk Number of persons at risk UI/ml UI/ml
  • 11. Impact of Antibodies on Beta- Agalsidase Efficacy in Fabry Disease Benichou et al. Molecular tools and genetics (2008) Shareofpatients withnon-zeroscore Serum negative Low titers Medium titers High titers
  • 12. Biosimilar = generic ‘Biosimilar’ is a biological that is similar to the originator biological but is not its generic due to differences in the initial raw materials and manufacturing of the originator biological and of the biosimilar… Source: translated from Article 10 (2) b of Directive 2001/83 as amended Why should we be cautious speaking about substitutability of biologicals?
  • 13. Regulation of biosimilar manufacturing and application in EC Amended Directive 2001/83/EC (2003/63/EC, 2004/27/EC) Overarching Guidelines (CHMP/437/04) Quality Guidelines (CHMP/49348/05) Non-Clin & Clin Guidelines (CHMP/42832/05) r-Human Insulin Guidance (CHMP/42832/05) Somatropin Guidance (CHMP/94528/05) r-GCSF Guidance (CHMP/31329/05) r-Erythropoeitin Guidance (CHMP/94526/05) Immunogenicity Guidance (CHMP/14327/06) Low Molecular Weight Heparin Guidance (CHMP/118264/2007) r--Interferon Guidance (CHMP/102046/06) Guidelines under preparation
  • 14. Findings of the Сomparative Alpha Epoietin Drug Study Singh A. K. Brigham and Women’s hospital & Harvard Medical School, Boston, USA. World Congress of Nephrology – Apr 22, 2007 47 samples from the following countries were tested: Argentine, Brazil, Columbia, India, Indonesia, Iran, Jordan, Korea, Lebanon, Nigeria, Philippines, Russia, Thailand, Venezuela, Viet Nam and Yemen The samples were tested according to the European Pharmacopoeia quality requirements to alpha epoietin. Eprex® (alpha epoietin) was used as a reference product. Singh AK. Poster presented at the World Congress of Nephrology, 21-25 April 2007, Rio de Janeiro, Brazil
  • 15. 15 Singh A. K. Study Findings  pH  9 samples deviated from the specification requirements  Osmosis  21 samples had greater osmosis  Protein and erythropoietin content  1 sample did not meet the specification requirements as concerns the protein content  8 samples had excess erythropoietin  In vitro biological sample 1 sample did not meet the specification requirements  18 samples deviated from the specification requirements  In vivo efficacy 48%-163% efficacy differences  9 samples did not meet the specification requirements  6 samples deviated from the specification requirements  Bacterial endotoxin 2 samples contained bacterial endotoxin Singh AK. Poster presented at the World Congress of Nephrology, 21-25 April 2007, Rio de Janeiro, Brazil
  • 16. 16  Aggregate content  29 samples exceeded the specification by the number of aggregates  7 samples had more than 1% and less than 2% aggregates  4 samples had 2%-4% aggregates  18 samples had more than 4% aggregates  Isoform content  34 samples had excess isoforms, which may reduce the clinical effect  9 out of 34 samples had ≥ 3 additional isoforms Singh A. K. Study Findings Singh AK. Poster presented at the World Congress of Nephrology, 21-25 April 2007, Rio de Janeiro, Brazil
  • 17. Alpha Epoietin Drug Comparative Study Findings (continued) Epoietin biosimilar In-vitro bio sample In-vivo efficacy on mice, % Bacterial endotoxin (EU/ml) Aggregates, % Standard (Eprex®) 80-125 80-125 < 2.5 < 1 Epocrim1 94 73 < 0.5 < 1 Epocrim2 175 76 < 0.5 2.4 Epokin 1 84 91 < 0.5 1.7 Epokrin 1 167 135 < 0.5 1.2 Epokrin 2 155 117 < 0.5 >4 Epokrin 3 175 149 < 0.5 < 1 Eporon 170 163 < 0.5 > 4 Epoet 141 95 < 0.5 2.7 Gerepo 141 48 < 0.5 > 4 Hemax 1 139 97 < 0.5 > 4 Hemax 2 132 101 < 0.5 > 4 Hemax 3 141 90 < 0.5 > 4 Hypercryte 153 113 < 0.5 > 4 Renogen 110 108 < 0.5 > 4 Vepox 177 57 > 2.5 > 4 Zirop 142 Two failures < 0.5 > 4
  • 18. Epokim 1 2 3 Epokrin 1 2 3 Eporon Epovet 1 2 Espogen 1 2 3 Geerepo Hemax 1 2 3 Hypercryte 1 2 Vepox Zirop 1 2 Alkali isoforms Acid isoforms 0 1 2 3 4 5 Total quantity of additional isoforms Alpha Epoietin Drug Comparative Study Findings (continued)
  • 19. Conclusions on Alpha Epoietin drug Comparative Study Findings:  Several out of the tested epoietin biosimilars had variable quality and efficacy; 42 out of 47 samples did not meet all European Requirements to alpha epoietin  34 samples contained additional alkali isoforms that may reduce clinical drug efficacy  2 samples contained bacterial endotoxin that poses risk for the patient’s safety  22 samples contained more than 2% aggregates that may influence the drug immunological profile  Detected differences lead to unpredictable adverse events in clinical practice  Studied biosimilars had differences in various series of one and the same drug Specialists applying epoietin generics in their practice should track their efficacy and safety attentively Singh AK. Poster presented at the World Congress of Nephrology, 21-25 April 2007, Rio de Janeiro, Brazil
  • 20. 20 July 09ASH Abstract & Poster # Immunogenicity of Low Molecular Weight Heparins and Their Biosimilars W.P.Jeske J.Walenga HIT Antibodies Synthesis Induction In Vitro Cross-Reactivity of Branded LMWHs (1 g/mL) with HIT Antibodies in the Platelet Aggregation Assay 1 2 3 4 5 6 7 8 %Aggregation 0 2 5 5 0 7 5 1. Saline 5. Reviparin 2. Dalteparin 6. Parnaparin 3. Enoxaparin 7. Tinzaparin 4. Nadroparin 8. Heparin In Vitro Cross-Reactivity of Branded LMWHs (1 g/mL) with HIT Antibodies in the Platelet Aggregation Assay 1 2 3 4 5 6 7 8 %Aggregation 0 2 5 5 0 7 5 1. Saline 5. Reviparin 2. Dalteparin 6. Parnaparin 3. Enoxaparin 7. Tinzaparin 4. Nadroparin 8. Heparin In Vitro Cross-Reactivity of Biosimilar Versions of Enoxaparin and Dalteparin (1 g/mL) with HIT Antibodies in the Platelet Aggregation Assay 1 2 3 4 5 6 7 %Aggregation 0 2 5 5 0 7 5 1. Saline 5. Dilutol 2. Clenox 6. Lupenox 3. Cutenox 7. Daltehep 4. Dripanina In Vitro Cross-Reactivity of Biosimilar Versions of Enoxaparin and Dalteparin (1 g/mL) with HIT Antibodies in the Platelet Aggregation Assay 1 2 3 4 5 6 7 %Aggregation 0 2 5 5 0 7 5 1. Saline 5. Dilutol 2. Clenox 6. Lupenox 3. Cutenox 7. Daltehep 4. Dripanina
  • 21. Clinical case: Clexan substitution with a generic A patient had taken Clexan for 4 years without complications. Upon transition to the enoxaparin biosimilar, the patient experienced 2 life- threatening haemorrhages within 4 months from the onset of use. This case suggests that FDA should follow EMA recommendation to have a more stringent biosimilar approval procedure: bioequivalency and the studies that display safety and efficacy similar to those of the originator before approval of the biosimilar. Biologicals and Biosimilars Clinical Case
  • 22. М.V. Belov, A.S. Petrochenko, E.M. Pozdnyakova, V.V. Yakusevich. Efficacy of different tromboembolic complication prevention methods in clinical practice (retrospective study). Clinical Pharmacology and Treatment, 2012, 21 (4) Biologicals and Biosimilars Clinical Pre-Surgical Practice Findings Goal. Assessing the efficacy of tromboembolic consequences prevention in the pre-surgery period using unfractionated heparin and enoxaparin biosimilar. Findings. Frequency of LLVT did not reliably differ in the patients receiving unfractionated heparin and enoxaparin biosimilar. Opinion. Lack of pronounced advantages of enoxaparin biosimilar to unfractionated heparin may be due to heterogeneity of the raw materials used for manufacturing of the originator and enoxaparin and biosimilar. Enoxaparin biosimilar did not differ from unfractionated heparin in terms of LLVT prevention efficacy. Frequency (%) of lower limb venous thrombosis before surgery (LLVT) Enoxaparin biosimilarUnfractionated heparin
  • 23. Immunogenicity Forecasting  Establishment of physical and chemical properties  Epitope analysis (in silico/in vitro)  Reactions with the patient’s serum  Animal tests • Conventionally used animals (relative immunogenicity?) • Subprimates • Immune tolerant transgenic mice
  • 24. Biosimilar Immunogenicity Issues  The existing analysis methods do not fully predict biological properties  The immune system is able to notice changes in a drug, which are not detected using analytical methods  Immunogenicity of biologicals may have significant clinical consequences 24
  • 25. Immunogenicity and Biosimilar Aspects  Immunogenicity can only be detected in clinical studies  Problems of trackability and substitutability with similars  Substitution must not be there the immunogenicity risk factor is  Immunogenicity may make a patient immune to a whole drug class  Standardization